Selected References:
- Clowse, M, et al. 2016. Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.Drug Saf. 39:755-762,
- Fernández-Sánchez M, et al. 2021. Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report. Birth Defects Res. 113(17):1275-1279.
- Mahadevan, U., et al 2018. Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databasesfor Ulcerative Colitis. Inflammatory Bowel Diseases, 24(12), 2494–2500.doi: 10.1093/ibd/izy160
- Mahadevan U, et al. 2019. Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group. Gastroenterology, 156(5), 1508-1524.
- Merren A, et al. 2015. Pregnancy Outcomes in the tofacitinib RA study database through April 2014.Abstract doi 10.1136/annrheumdis-2015-eular.3547.
- Picardo S, Seow CH. 2019. A Pharmacological Approach to Managing Inflammatory Bowel Disease During Conception, Pregnancy and Breastfeeding: Biologic and Oral Small Molecule Therapy. Drugs;79(10):1053-1063.
